Anxiety disorders and depression treatment Market by Drug Class (SSRIs, SNRIs, TeCAs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers), Pipeline Analysis (Brintellix (Vortioxetine - Lu AA21004), ALKS-5461, Brexpiprazole (OPC-34712)) - Global Opportunity Analysis and Industry Forecast, 2019-2026

Healthcare	LI_18592	Pages: NA	Jan 2020 \| 3478 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Depression and anxiety disorders are the most common psychiatric disorders affecting a huge population across the globe. Depression; is related to a state of emotion that further affects actions, thoughts and sometimes the sleeping pattern of the concerned person. Depression is the most common type of mental disorder affecting nearly 350 million patients of varied scale age groups, whereas, anxiety is a reaction to stress. Extreme level of anxiety result in anxiety disorders which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder.

The rising geriatric population, reduced side effects and greater efficacy of new/innovative drugs along with the accelerating prevalence of anxiety & depression disorders are contributing towards the growth of this market. However, patent expiry for majority of the drugs, dry pipeline for the novel drugs, mental disorders that are drug-resistant and growing numbers of different generic drugs are analysed to impede the anxiety disorders and depression treatment market growth. The prospect of innovations and developments in herbal remedies with an improved distribution network is offers potential opportunities for the key participants.

The global anxiety disorders and depression treatment market is segmented on the basis of drug class, pipeline analysis and geography. The drug class segment is further categorized into SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers and Others. On the basis of pipeline analysis, the market is segmented into Brintellix (Vortioxetine - Lu AA21004), ALKS-5461 and Brexpiprazole (OPC-34712). The progressive outcomes of clinical trials for the related drugs and their anticipated commercialization in the forecast period will drive the growth for anxiolytic and antidepressant drugs in the future. Geographically, the global anxiety disorders and depression treatment market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America accounts for the largest market share, contributed by the U.S. due to the presence of various branded formulations influencing the market dynamics extensively.

Key companies profiled in this market include Eli Lilly and Company, Forest Laboratories, Inc., AstraZeneca PLC, Sanofi-Aventis, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson and others. Recent developments, Clinical research, geographical expansion and enhanced distribution networks are the key strategies adopted by the key participants.

KEY BENEFITS

In-depth coverage of the global anxiety disorders and depression treatment market including key drivers, restraints and opportunities would help professionals to better understand market inclination
Drug class market is comprehensively analyzed on the basis of drug launch, expiry, sales/revenue, efficacy of the drugs and geographical presence of market leaders
The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 in terms of value
Detailed study of the strategies of key leaders, partnerships and acquisitions in the global anxiety disorders and depression treatment market would be informative for professionals in the corporate sector
Pin-point analysis of geographic segments helps to identify opportunities for growth within the anxiety disorders and depression treatment Market
Identification of key investment pockets for anxiety disorders and depression treatment market, provide strategic assistance to decision makers
Market attractiveness analysis, has been included for various product segments, therapeutics, devices and geographic regions along with a detailed analysis of factors responsible for rapid growth of the market segments

KEY MARKET SEGMENTS

The global anxiety disorders and depression treatment Market is segmented into three major categories: drug class, pipeline analysis and geography.

MARKET BY DRUG CLASS

SSRIs (Selective Serotonin Reuptake Inhibitors)
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
TeCAs (Tetracyclic Antidepressants)
TCAs (Tricyclic Antidepressants)
MAOIs (Monoamine Oxidase inhibitors)
Atypical Antipsychotics
Benzodiazepines
Anticonvulsants
Beta-Blockers
Others

MARKET BY PIPELINE ANALYSIS

Brintellix (Vortioxetine - Lu AA21004)
ALKS-5461
Brexpiprazole (OPC-34712)

MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com